Brussels, 12th September 2017
• For the first time the brand new ‘2017 Market Review – Biosimilar Medicines Markets’ provides a detailed overview of biosimilar medicines policies in 31 European countries.
• Countries and regions have implemented a variety of policies for biosimilar medicines with varying degrees of success. Tailor-made policies, taking into account the different market characteristics, are essential success factors for health systems.